- Conditions
- Prevention of Thromboembolic Events, Atrial Fibrillation
- Interventions
- Apixaban
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced May 21, 2026, 10:10 PM EDT